Holen Sie sich die Stockscreener-App
89.07
1.13%
-1.02
Handel nachbörslich:
89.07
Schlusskurs vom Vortag:
$90.09
Offen:
$90.11
24-Stunden-Volumen:
3.10M
Relative Volume:
0.94
Marktkapitalisierung:
$51.34B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
48.39
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
+2.85%
1M Leistung:
+2.59%
6M Leistung:
+11.73%
1J Leistung:
+16.39%
1-Tages-Spanne:
$88.97
$91.05
1-Wochen-Bereich:
$86.55
$91.05
52-Wochen-Spanne:
$74.66
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
89.07 | 51.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
103.70 | 179.44B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.41 | 122.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.15 | 117.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.69 | 66.22B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Overweight |
| 2026-07-28 | Eingeleitet | UBS | Buy |
| 2026-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - Zacks Investment Research
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death - Benzinga
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death - Yahoo Finance Singapore
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corporation $EW Stock Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc. - MarketBeat
Baird Adjusts Price Target on Edwards Lifesciences to $90 From $94 - Yahoo Finance
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Earnings Preview: What to Expect - Yahoo Finance
Edwards Lifesciences Earnings Preview: What to Expect - Barchart.com
Edwards Lifesciences Earnings Preview: What to Expect - inkl
Edwards Lifesciences Corporation (EW) Options ChainYahoo Finance - Yahoo! Finance Canada
Edwards Lifesciences Corporation (EW) Options Chain - Yahoo! Finance Canada
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock - Investing.com
Edwards Lifesciences Corp (EW) Insider Daniel Lippis Sells 619 S - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Is Edwards Lifesciences (NYSE:EW) Entering A Stronger Phase? - Kalkine Media
Why Edwards Lifesciences (EW) Stock Is Falling Today - Quiver Quantitative
UBS reiterates Edwards Lifesciences stock rating on endpoint expectations - Investing.com
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? - Zacks Investment Research
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - BioSpace
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - Yahoo Finance
Edwards Lifesciences Corp (CEUX:EWLd) Stock Earnings Transcripts - GuruFocus
Edwards Lifesciences (NYSE:EW) Share Price Breaks Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
What Does Expanded TAVR Coverage Mean for Edwards Lifesciences (NYSE:EW)? - Kalkine Media
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating - Yahoo Finance
Edwards Lifesciences to Host Investor Event in Conjunction With TCT - Yahoo Finance
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve - Benzinga
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating - marketscreener.com
Edwards Lifesciences (NYSE:EW) Stock Forecast & Analyst Predictions - Simply Wall Street
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients - BioSpace
Edwards Lifesciences wins FDA approval for AUTUS - Mugglehead Investment Magazine
Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adj - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Receives FDA Approval For AUTUS Size-Adjustable Valve - marketscreener.com
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Edwards Lifesciences Corporation Stocks - tradingview.com
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edwards Lifesciences Corp-Aktie (EW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR |
Oct 08 '26 |
Sale |
85.65 |
619 |
53,017 |
40,034 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Option Exercise |
72.68 |
619 |
44,989 |
40,653 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Sale |
87.51 |
619 |
54,169 |
40,034 |
| Dahl Andrew M. | SVP, Corporate Controller |
Aug 31 '26 |
Sale |
91.06 |
544 |
49,534 |
14,868 |
| Dahl Andrew M. | Officer |
Aug 31 '26 |
Proposed Sale |
91.06 |
544 |
49,534 |
0 |
| Bruls Annette | CVP, EMEACLA |
Aug 28 '26 |
Sale |
89.98 |
2,644 |
237,907 |
17,984 |
| Bruls Annette | Officer |
Aug 28 '26 |
Proposed Sale |
89.98 |
2,644 |
237,907 |
0 |
| Markowitz Wayne | CVP, JAPAC |
Aug 26 '26 |
Sale |
91.47 |
1,240 |
113,417 |
20,294 |
| Markowitz Wayne | Officer |
Aug 26 '26 |
Proposed Sale |
91.47 |
1,240 |
113,417 |
0 |
| Chopra Daveen | Officer |
Aug 26 '26 |
Proposed Sale |
91.02 |
31,800 |
2,894,440 |
0 |
0.70%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):